Redwood Investment Management LLC Acquires Shares of 4,168 West Pharmaceutical Services, Inc. $WST

Redwood Investment Management LLC bought a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,168 shares of the medical instruments supplier’s stock, valued at approximately $1,045,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Brendel Financial Advisors LLC acquired a new position in West Pharmaceutical Services during the fourth quarter valued at approximately $3,742,000. Bank of Nova Scotia boosted its stake in West Pharmaceutical Services by 337.8% in the first quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock valued at $16,373,000 after buying an additional 50,402 shares in the last quarter. Birch Hill Investment Advisors LLC grew its position in West Pharmaceutical Services by 11.5% in the fourth quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier’s stock valued at $41,862,000 after acquiring an additional 15,678 shares during the last quarter. Annex Advisory Services LLC raised its stake in West Pharmaceutical Services by 8.7% during the fourth quarter. Annex Advisory Services LLC now owns 122,958 shares of the medical instruments supplier’s stock worth $33,831,000 after acquiring an additional 9,800 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its stake in shares of West Pharmaceutical Services by 23.3% in the 4th quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock valued at $40,425,000 after purchasing an additional 27,745 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on WST shares. Morgan Stanley raised their target price on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Evercore reissued an “outperform” rating and set a $425.00 target price on shares of West Pharmaceutical Services in a report on Monday, July 27th. KeyCorp upped their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research report on Thursday, July 2nd. Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Finally, BNP Paribas Exane began coverage on West Pharmaceutical Services in a report on Monday, July 13th. They set an “outperform” rating and a $447.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $368.08.

West Pharmaceutical Services Stock Performance

NYSE WST opened at $347.75 on Tuesday. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The company has a fifty day simple moving average of $340.42 and a 200 day simple moving average of $290.17. West Pharmaceutical Services, Inc. has a 12-month low of $223.83 and a 12-month high of $386.00. The company has a market cap of $24.47 billion, a P/E ratio of 44.53, a PEG ratio of 2.38 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $2.08 by $0.29. The business had revenue of $872.30 million for the quarter, compared to analysts’ expectations of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Sell-side analysts predict that West Pharmaceutical Services, Inc. will post 8.94 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be issued a dividend of $0.22 per share. The ex-dividend date is Wednesday, July 29th. This represents a $0.88 annualized dividend and a yield of 0.3%. West Pharmaceutical Services’s payout ratio is 11.27%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.